



## Clinical trial results:

**Phase III, non-randomised, open-label study to evaluate the safety and immunogenicity of a prime-boost schedule of the H1N1 candidate vaccine adjuvanted with AS03B administered to subjects aged 3 to 17 years.**

### Summary

EudraCT number	2009-015011-41
Trial protocol	DE
Global end of trial date	22 November 2010

### Results information

Result version number	v2 (current)
This version publication date	06 March 2021
First version publication date	31 May 2015
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li><li>• Minor corrections in safety section.</li></ul>

### Trial information

#### Trial identification

Sponsor protocol code	113638
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00972517
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-000725-PIP01-09
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 November 2010
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 November 2010
Global end of trial reached?	Yes
Global end of trial date	22 November 2010
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the humoral immune response after two primary administrations of the candidate H1N1 pandemic vaccine that meets or exceeds the EMEA (CHMP) guidance targets for pandemic vaccine seroconversion rate (SCR), seroprotection rate (SPR) and geometric mean fold rise (GMFR) at 21 days after the second dose of H1N1 vaccine in children aged 3 to 17 years.

To evaluate the superiority in terms of vaccine virus homologous haemagglutination inhibition (HI) antibody response of a single dose of the H1N1 candidate vaccine administered as a 6-month booster after 2-dose primary vaccination compared to the response after the first dose of primary vaccination.

Protection of trial subjects:

The subjects were observed closely for at least 30 minutes, with appropriate medical treatment readily available in case of anaphylaxis following the administration of vaccines.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	29 September 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 245
Worldwide total number of subjects	245
EEA total number of subjects	245

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	123
Adolescents (12-17 years)	122
Adults (18-64 years)	0

From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

One subject was enrolled but not vaccinated and therefore, was not included in the number of subjects under "started".

### Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

### Period 1

Period 1 title	At Day 21 (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	No
<b>Arm title</b>	Flu BS1_3-5 Years Group

Arm description:

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

On Day 0 (before the first vaccination);  
On Day 21 (before the second vaccination);  
On Day 42 (21 days after the second vaccination);  
At Month 6 (6 months after the first vaccination);

Arm type	Experimental
Investigational medicinal product name	Pandemrix
Investigational medicinal product code	GSK2340272A
Other name	GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03
Pharmaceutical forms	Emulsion for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

<b>Arm title</b>	Flu BS1_6-9 Years Group
------------------	-------------------------

Arm description:

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

On Day 0 (before the first vaccination);  
On Day 21 (before the second vaccination);  
On Day 42 (21 days after the second vaccination);  
At Month 6 (6 months after the first vaccination);

Arm type	Experimental
Investigational medicinal product name	Pandemrix
Investigational medicinal product code	GSK2340272A
Other name	GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03
Pharmaceutical forms	Emulsion for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm

<b>Arm title</b>	Flu BS1_10-17 Years Group
------------------	---------------------------

**Arm description:**

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

- On Day 0 (before the first vaccination);
- On Day 21 (before the second vaccination);
- On Day 42 (21 days after the second vaccination);
- At Month 6 (6 months after the first vaccination);

Arm type	Experimental
Investigational medicinal product name	Pandemrix
Investigational medicinal product code	GSK2340272A
Other name	GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03
Pharmaceutical forms	Emulsion for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

<b>Arm title</b>	Flu BS2_3-5 Years Group
------------------	-------------------------

**Arm description:**

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

- On Day 42 (21 days after the second vaccination);
- At Month 6 (6 months after the first vaccination);
- At Month 12 (one year after the first vaccination).

Arm type	Experimental
Investigational medicinal product name	Pandemrix
Investigational medicinal product code	GSK2340272A
Other name	GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03
Pharmaceutical forms	Emulsion for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

<b>Arm title</b>	Flu BS2_6-9 Years Group
------------------	-------------------------

**Arm description:**

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

- On Day 42 (21 days after the second vaccination);
- At Month 6 (6 months after the first vaccination);
- At Month 12 (one year after the first vaccination).

Arm type	Experimental
Investigational medicinal product name	Pandemrix
Investigational medicinal product code	GSK2340272A
Other name	GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03
Pharmaceutical forms	Emulsion for injection

Routes of administration	Intramuscular use
--------------------------	-------------------

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

<b>Arm title</b>	Flu BS2_10-17 Years Group
------------------	---------------------------

Arm description:

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

On Day 42 (21 days after the second vaccination);

At Month 6 (6 months after the first vaccination);

At Month 12 (one year after the first vaccination).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Pandemrix
--	-----------

Investigational medicinal product code	GSK2340272A
--	-------------

Other name	GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03
------------	--

Pharmaceutical forms	Emulsion for injection
----------------------	------------------------

Routes of administration	Intramuscular use
--------------------------	-------------------

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

<b>Arm title</b>	Flu pooled_3-5 Years Group
------------------	----------------------------

Arm description:

Pooled data of subjects aged 3 to 5 years from the Flu BS1 and Flu BS2 Groups

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Pandemrix
--	-----------

Investigational medicinal product code	GSK2340272A
--	-------------

Other name	GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03
------------	--

Pharmaceutical forms	Emulsion for injection
----------------------	------------------------

Routes of administration	Intramuscular use
--------------------------	-------------------

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

<b>Arm title</b>	Flu pooled_6-9 Years Group
------------------	----------------------------

Arm description:

Pooled data of subjects aged 6 to 9 years from the Flu BS1 and Flu BS2 Groups

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Pandemrix
--	-----------

Investigational medicinal product code	GSK2340272A
--	-------------

Other name	GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03
------------	--

Pharmaceutical forms	Emulsion for injection
----------------------	------------------------

Routes of administration	Intramuscular use
--------------------------	-------------------

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

<b>Arm title</b>	Flu pooled_10-17 Years Group
------------------	------------------------------

Arm description:

Pooled data of subjects aged 10 to 17 years from the Flu BS1 and Flu BS2 Groups

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Pandemrix
Investigational medicinal product code	GSK2340272A
Other name	GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03
Pharmaceutical forms	Emulsion for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

<b>Number of subjects in period 1</b>	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group
Started	31	31	60
Completed	31	30	60
Not completed	0	1	0
Consent withdrawn by subject	-	1	-
Adverse event, non-fatal	-	-	-

<b>Number of subjects in period 1</b>	Flu BS2_3-5 Years Group	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group
Started	30	34	58
Completed	27	33	58
Not completed	3	1	0
Consent withdrawn by subject	2	1	-
Adverse event, non-fatal	1	-	-

<b>Number of subjects in period 1</b>	Flu pooled_3-5 Years Group	Flu pooled_6-9 Years Group	Flu pooled_10-17 Years Group
Started	61	65	118
Completed	58	63	118
Not completed	3	2	0
Consent withdrawn by subject	2	2	-
Adverse event, non-fatal	1	-	-

## Baseline characteristics

### Reporting groups<sup>[1]</sup>

Reporting group title	At Day 21
-----------------------	-----------

Reporting group description: -

Notes:

[1] - The number of subjects reported to be in the baseline period is not equal to the worldwide number of subjects enrolled in the trial. It is expected that these numbers will be the same.

Justification: Out of the 245 subjects enrolled in this trial, 1 subject did not receive vaccination even though the subject number had been allocated; hence he/she was excluded from the study start.

Reporting group values	At Day 21	Total	
Number of subjects	244	244	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
geometric mean	9.2		
standard deviation	± 4.15	-	
Gender categorical			
Units: Subjects			
Female	116	116	
Male	128	128	

## End points

---

### End points reporting groups

---

Reporting group title	Flu BS1_3-5 Years Group
-----------------------	-------------------------

---

Reporting group description:

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

- On Day 0 (before the first vaccination);
- On Day 21 (before the second vaccination);
- On Day 42 (21 days after the second vaccination);
- At Month 6 (6 months after the first vaccination);

---

Reporting group title	Flu BS1_6-9 Years Group
-----------------------	-------------------------

---

Reporting group description:

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

- On Day 0 (before the first vaccination);
- On Day 21 (before the second vaccination);
- On Day 42 (21 days after the second vaccination);
- At Month 6 (6 months after the first vaccination);

---

Reporting group title	Flu BS1_10-17 Years Group
-----------------------	---------------------------

---

Reporting group description:

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

- On Day 0 (before the first vaccination);
- On Day 21 (before the second vaccination);
- On Day 42 (21 days after the second vaccination);
- At Month 6 (6 months after the first vaccination);

---

Reporting group title	Flu BS2_3-5 Years Group
-----------------------	-------------------------

---

Reporting group description:

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

- On Day 42 (21 days after the second vaccination);
- At Month 6 (6 months after the first vaccination);
- At Month 12 (one year after the first vaccination).

---

Reporting group title	Flu BS2_6-9 Years Group
-----------------------	-------------------------

---

Reporting group description:

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

- On Day 42 (21 days after the second vaccination);
- At Month 6 (6 months after the first vaccination);
- At Month 12 (one year after the first vaccination).

---

Reporting group title	Flu BS2_10-17 Years Group
-----------------------	---------------------------

---

Reporting group description:

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

- On Day 42 (21 days after the second vaccination);
- At Month 6 (6 months after the first vaccination);
- At Month 12 (one year after the first vaccination).

---

Reporting group title	Flu pooled_3-5 Years Group
-----------------------	----------------------------

---

Reporting group description:

Pooled data of subjects aged 3 to 5 years from the Flu BS1 and Flu BS2 Groups

---

Reporting group title	Flu pooled_6-9 Years Group
-----------------------	----------------------------

---

Reporting group description:

Pooled data of subjects aged 6 to 9 years from the Flu BS1 and Flu BS2 Groups

---

Reporting group title	Flu pooled_10-17 Years Group
Reporting group description:	
Pooled data of subjects aged 10 to 17 years from the Flu BS1 and Flu BS2 Groups	

**Primary: Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain**

End point title	Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain <sup>[1][2]</sup>
-----------------	---

End point description:

Antibody titers were expressed as Geometric mean titers (GMTs).

End point type	Primary
----------------	---------

End point timeframe:

At Day 0, Day 21 and Day 42

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This outcome was descriptive; hence no statistical analyses were required.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	Flu BS2_3-5 Years Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	54	25 <sup>[3]</sup>
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1, Day 0	5.7 (4.5 to 7.2)	5.2 (4.8 to 5.8)	9.9 (7 to 14.1)	0 (0 to 0)
H1N1, Day 21	192.6 (145.6 to 254.8)	190.3 (147 to 246.3)	479.3 (361.8 to 634.9)	0 (0 to 0)
H1N1, Day 42	1361.7 (1107 to 1674.9)	970.1 (765.8 to 1228.8)	1069.4 (892.6 to 1281.3)	1161.7 (905.2 to 1490.9)

Notes:

[3] - This outcome measure was assessed only at Day 42 for the Flu BS2\_3-5 Years Group.

End point values	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30 <sup>[4]</sup>	57 <sup>[5]</sup>		
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1, Day 0	0 (0 to 0)	0 (0 to 0)		
H1N1, Day 21	0 (0 to 0)	0 (0 to 0)		
H1N1, Day 42	915.7 (759.1 to 1104.6)	979.6 (845.3 to 1135.2)		

Notes:

[4] - This outcome measure was assessed only at Day 42 for the Flu BS2\_6-9 Years Group.

[5] - This outcome measure was assessed only at Day 42 for the Flu BS2\_10-17 Years Group.

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of seroconverted subjects for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain

End point title	Number of seroconverted subjects for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain <sup>[6][7]</sup>
-----------------	--

End point description:

A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (<) 1:10 and a post-vaccination titre greater than or equal to ( $\geq$ ) 1:40 or a pre-vaccination titre  $\geq$  1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (>) 40% in children aged 3 to 17 years.

End point type	Primary
----------------	---------

End point timeframe:

At Day 42

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This outcome was descriptive; hence no statistical analyses were required.

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	28	30	54	
Units: Subjects				
H1N1	28	30	53	

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain

End point title	Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain <sup>[8][9]</sup>
-----------------	---

End point description:

A seroprotected subject was defined as a vaccinated subject with a serum HI titre greater than or equal to ( $\geq$ ) 1:40, that usually is accepted as indicating protection. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the post-vaccination time point estimate for SPR the point estimate for SPR was greater than (>) 70% in children aged 3 to 17 years.

End point type	Primary
----------------	---------

End point timeframe:

At Day 42

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This outcome was descriptive; hence no statistical analyses were required.

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	28	30	54	
Units: Subjects				
H1N1	28	30	54	

## Statistical analyses

No statistical analyses for this end point

### Primary: HI antibody geometric mean fold rise (GMFR) against the Flu A/California/7/2009 (H1N1) virus strain

End point title	HI antibody geometric mean fold rise (GMFR) against the Flu A/California/7/2009 (H1N1) virus strain <sup>[10][11]</sup>
-----------------	---

End point description:

GMFR, also called seroconversion factor (SCF), was defined as the fold increase in serum HI GMTs post-vaccination compared to pre-vaccination. The CHMP criterion was fulfilled if the point estimate for GMFR was greater than (>) 2.5 in children aged 3 to 17 years

End point type	Primary
----------------	---------

End point timeframe:

At Day 42

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This outcome was descriptive; hence no statistical analyses were required.

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	28	30	54	
Units: Fold increase				
geometric mean (confidence interval 95%)				
H1N1	237.68 (175.28 to 322.29)	185.25 (142.09 to 241.52)	107.74 (76.64 to 151.45)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain

End point title Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain<sup>[12]</sup>

End point description:

Antibody titers were expressed as geometric mean titers (GMTs)

End point type Secondary

End point timeframe:

At Month 6

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	Flu BS2_3-5 Years Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27	28	53	23
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1	140.8 (118.2 to 167.6)	154.2 (126.5 to 187.9)	254.6 (199 to 325.7)	129.4 (94.6 to 176.9)

End point values	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	47		
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1	148.2 (119 to 184.4)	243.6 (185.9 to 319.3)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain

End point title Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain<sup>[13]</sup>

End point description:

Antibody titers were expressed as geometric mean titers (GMTs)

End point type	Secondary			
End point timeframe:	At Month 12			
Notes:	<p>[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.</p> <p>Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.</p>			
<b>End point values</b>	Flu BS2_3-5 Years Group	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	20	26	41	
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1	48.5 (35.7 to 65.7)	60.5 (49.2 to 74.3)	132.8 (94.9 to 185.8)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seroconverted subjects for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain

End point title	Number of seroconverted subjects for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain <sup>[14]</sup>
-----------------	--

End point description:

A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (<) 1:10 and a post-vaccination titre greater than or equal to (≥) 1:40 or a pre-vaccination titre ≥ 1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (>) 40% in children aged 3 to 17 years.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 6

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	27	28	53	
Units: Subjects				
H1N1	27	28	50	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain

End point title	Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain <sup>[15]</sup>
-----------------	---

End point description:

A seroprotected subject was defined as a vaccinated subject with a serum HI titre greater than or equal to ( $\geq$ ) 1:40, that usually is accepted as indicating protection. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the post-vaccination time point estimate for SPR the point estimate for SPR was greater than ( $>$ ) 70% in children aged 3 to 17 years.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 6

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	Flu BS2_3-5 Years Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27	28	53	23
Units: Subjects				
H1N1	27	28	53	20

End point values	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	47		
Units: Subjects				
H1N1	27	47		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects who were seroprotected for HI antibodies against

## the Flu A/California/7/2009 (H1N1) virus strain

End point title	Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain <sup>[16]</sup>
-----------------	---

### End point description:

A seroprotected subject was defined as a vaccinated subject with a serum HI titre greater than or equal to ( $\geq$ ) 1:40, that usually is accepted as indicating protection. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the post-vaccination time point estimate for SPR the point estimate for SPR was greater than ( $>$ ) 70% in children aged 3 to 17 years.

End point type	Secondary
----------------	-----------

### End point timeframe:

At Month 12

### Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	Flu BS2_3-5 Years Group	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	20	26	41	
Units: Subjects				
H1N1	17	22	37	

## Statistical analyses

No statistical analyses for this end point

## Secondary: HI antibody geometric mean fold rise (GMFR) against the Flu A/California/7/2009 (H1N1) virus strain

End point title	HI antibody geometric mean fold rise (GMFR) against the Flu A/California/7/2009 (H1N1) virus strain <sup>[17]</sup>
-----------------	---

### End point description:

GMFR, also called seroconversion factor (SCF), was defined as the fold increase in serum HI GMTs post-vaccination compared to pre-vaccination. The CHMP criterion was fulfilled if the point estimate for GMFR was greater than ( $>$ ) 2.5 in children aged 3 to 17 years

End point type	Secondary
----------------	-----------

### End point timeframe:

At Month 6

### Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	27	28	53	
Units: Fold increase				
geometric mean (confidence interval 95%)				
H1N1	27.44 (22.42 to 33.57)	29.35 (23.53 to 36.61)	25.32 (18.6 to 34.47)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Humoral immune response in terms of neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) vaccine strain

End point title	Humoral immune response in terms of neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) vaccine strain <sup>[18]</sup>
-----------------	--

End point description:

Antibody titers were expressed as Geometric mean titers (GMTs). This analysis was conducted on a subset of one third of the subjects who were randomly selected.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 0, Day 21, Day 42 and Month 6

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	Flu BS2_3-5 Years Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	15	14	12 <sup>[19]</sup>
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1, Day 0	4.9 (3.9 to 6.1)	7.1 (3.9 to 12.7)	8 (3 to 21.3)	0 (0 to 0)
H1N1, Day 21	27.7 (13 to 58.8)	65.9 (24.6 to 176.4)	109.4 (34.5 to 346.7)	0 (0 to 0)
H1N1, Day 42	433.2 (295.2 to 635.6)	473.7 (301.5 to 744.1)	438.4 (191.3 to 1004.8)	533.4 (298.4 to 953.7)
H1N1, Month 6	158.9 (110.4 to 228.8)	203.3 (133.7 to 309.3)	232.1 (81.8 to 658.4)	156.6 (89.8 to 273.3)

Notes:

[19] - This outcome measure was assessed only at Day 42 and Month 6 for the Flu BS2 Group.

<b>End point values</b>	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	15 <sup>[20]</sup>		

Units: Titer				
geometric mean (confidence interval 95%)				
H1N1, Day 0	0 (0 to 0)	0 (0 to 0)		
H1N1, Day 21	0 (0 to 0)	0 (0 to 0)		
H1N1, Day 42	260.1 (141.9 to 476.6)	199.5 (112.7 to 353.2)		
H1N1, Month 6	166 (88.7 to 310.6)	150.9 (62.7 to 363.1)		

Notes:

[20] - This outcome measure was assessed only at Day 42 and Month 6 for the Flu BS2 Group.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Humoral immune response in terms of neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) vaccine strain

End point title	Humoral immune response in terms of neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) vaccine strain <sup>[21]</sup>
-----------------	--

End point description:

Antibody titers were expressed as Geometric mean titers (GMTs). This analysis was conducted on a subset of one third of the subjects who were randomly selected.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 12

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	Flu BS2_3-5 Years Group	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	11	12	12	
Units: Titer				
geometric mean (confidence interval 95%)				
H1N1	152.3 (88.8 to 261)	129.9 (71.2 to 236.8)	138.3 (71.6 to 267.2)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seroconverted subjects for neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) virus strain

End point title	Number of seroconverted subjects for neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) virus strain <sup>[22]</sup>
-----------------	---

End point description:

A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (<) 1:10 and a post-vaccination titre greater than or equal to ( $\geq$ ) 1:40 or a pre-vaccination titre  $\geq$  1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (>) 40% in children aged 3 to 17 years. This analysis was conducted on a subset of one third of the subjects who were randomly selected.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 21 and Day 42

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	16	15	14	
Units: Subjects				
H1N1, Day 21	8	10	9	
H1N1, Day 42	15	15	14	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seroconverted subjects for neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) virus strain

End point title	Number of seroconverted subjects for neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) virus strain <sup>[23]</sup>
-----------------	---

End point description:

A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (<) 1:10 and a post-vaccination titre greater than or equal to ( $\geq$ ) 1:40 or a pre-vaccination titre  $\geq$  1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (>) 40% in children aged 3 to 17 years. This analysis was conducted on a subset of one third of the subjects who were randomly selected.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 6

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	16	15	13	
Units: Subjects				
H1N1	16	14	12	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects reporting Any and Grade 3 solicited local symptoms

End point title	Number of subjects reporting Any and Grade 3 solicited local symptoms <sup>[24]</sup>
-----------------	---

End point description:

Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as significant pain at rest that prevented normal everyday activities as assessed by inability to attend/do work or school or cried when limb was moved/spontaneously painful. Grade 3 redness and swelling was greater than 50 millimeters (mm) i.e. > 50mm.

End point type	Secondary
----------------	-----------

End point timeframe:

During the 7-day (Days 0-6) post-vaccination period

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	Flu pooled_3-5 Years Group	Flu pooled_6-9 Years Group	Flu pooled_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	60	65	118	
Units: Subjects				
Any Pain	40	49	96	
Grade 3 Pain	4	9	11	
Any Redness	28	28	46	
Grade 3 Redness	4	2	4	
Any Swelling	22	22	46	
Grade 3 Swelling	2	3	10	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects reporting Any, Grade 3 and Related solicited general symptoms

End point title	Number of subjects reporting Any, Grade 3 and Related solicited general symptoms <sup>[25]</sup>
-----------------	--

End point description:

Solicited general symptoms assessed were arthralgia, diarrhoea, drowsiness, fatigue, gastro-intestinal symptoms, headache, irritability, loss of appetite, myalgia, shivering, sweating and fever [axillary temperature above 37.5 degrees Celsius (°C)]. Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary temperature above 39.0°C

End point type Secondary

End point timeframe:

During the 7-day (Days 0-6) post-vaccination period

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	Flu pooled_3-5 Years Group	Flu pooled_6-9 Years Group	Flu pooled_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	60	65	118	
Units: Subjects				
Any Arthralgia	0	14	25	
Grade 3 Arthralgia	0	1	3	
Related Arthralgia	0	14	23	
Any Diarrhoea	9	0	0	
Grade 3 Diarrhoea	2	0	0	
Related Diarrhoea	5	0	0	
Any Drowsiness	20	0	0	
Grade 3 Drowsiness	3	0	0	
Related Drowsiness	18	0	0	
Any Fatigue	0	24	53	
Grade 3 Fatigue	0	4	6	
Related Fatigue	0	23	50	
Any Gastro-intestinal symptoms	0	13	30	
Grade 3 Gastro-intestinal symptoms	0	1	5	
Related Gastro-intestinal symptoms	0	10	23	
Any Headache	0	19	61	
Grade 3 Headache	0	4	10	
Related Headache	0	19	56	
Any Irritability	18	0	0	
Grade 3 Irritability	1	0	0	
Related Irritability	18	0	0	
Any Loss of appetite	18	0	0	
Grade 3 Loss of appetite	1	0	0	
Related Loss of appetite	17	0	0	
Any Myalgia	0	13	45	
Grade 3 Myalgia	0	1	3	
Related Myalgia	0	13	43	
Any Shivering	10	10	35	
Grade 3 Shivering	0	0	3	
Related Shivering	9	9	33	
Any Sweating	9	10	18	

Grade 3 Sweating	0	0	1	
Related Sweating	8	9	15	
Any Fever ( $\geq 37.5^{\circ}\text{C}$ )	27	13	30	
Grade 3 Fever ( $> 39^{\circ}\text{C}$ )	4	3	4	
Related Fever	23	11	23	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects reporting any Medically Attended Adverse Events (MAEs)

End point title	Number of subjects reporting any Medically Attended Adverse Events (MAEs) <sup>[26]</sup>
-----------------	---

End point description:

MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (Day 0 to Month 12)

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	Flu BS2_3-5 Years Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	31	31	60	30
Units: Subjects				
Subjects with any MAE(s)	22	19	36	24

End point values	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	58		
Units: Subjects				
Subjects with any MAE(s)	16	34		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects reporting any Adverse Events of Specific Interest

## (AESI)/potential immune-mediated diseases (pIMDs)

End point title	Number of subjects reporting any Adverse Events of Specific Interest (AESI)/potential immune-mediated diseases (pIMDs) <sup>[27]</sup>
-----------------	--

### End point description:

Potential immune-mediated diseases (pIMDs) were defined as a subset of adverse events that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which might or might not have an autoimmune etiology. "Any pIMD" was defined as at least one pIMD experienced by the study subject.

End point type	Secondary
----------------	-----------

### End point timeframe:

During the entire study period (Day 0 to Month 12)

### Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	Flu pooled_3-5 Years Group	Flu pooled_6-9 Years Group	Flu pooled_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	61	65	118	
Units: Subjects				
Subjects with any AESI(s)/pIMD(s)	0	0	0	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects reporting any, grade 3 and related unsolicited adverse events (AEs).

End point title	Number of subjects reporting any, grade 3 and related unsolicited adverse events (AEs). <sup>[28]</sup>
-----------------	---

### End point description:

An unsolicited AE was defined as any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.

End point type	Secondary
----------------	-----------

### End point timeframe:

Within the 84-day after the first vaccination or from 63-day follow-up period after the second vaccination

### Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	Flu pooled_3-5 Years Group	Flu pooled_6-9 Years Group	Flu pooled_10-17 Years Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	61	65	118	
Units: Subjects				
Any AE(s)	42	25	53	
Grade 3 AE(s)	3	1	5	
Related AE(s)	9	2	4	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects reporting any and related serious adverse events (SAEs)

End point title	Number of subjects reporting any and related serious adverse events (SAEs) <sup>[29]</sup>
-----------------	--

End point description:

A serious adverse event was any untoward medical occurrence that: resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period (Day 0 to Month 12)

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	Flu BS2_3-5 Years Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	31	31	60	30
Units: Subjects				
Any SAE(s)	1	1	1	1
Related SAE(s)	0	0	0	0

<b>End point values</b>	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	58		
Units: Subjects				
Any SAE(s)	0	3		
Related SAE(s)	0	0		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with normal and abnormal haematological and biochemistry parameters with respect to Alanine aminotransferase (ALAT), Aspartate aminotransferase (ASAT), Total Bilirubin, Bilirubin Conjugated / Direct, Creatine and Blood urea nitrogen (BUN)

End point title	Number of subjects with normal and abnormal haematological and biochemistry parameters with respect to Alanine aminotransferase (ALAT), Aspartate aminotransferase (ASAT), Total Bilirubin, Bilirubin Conjugated / Direct, Creatine and Blood urea nitrogen (BUN) <sup>[30]</sup>
-----------------	---

End point description:

Subjects were categorized by age and according to their results at pre-vaccination (Day 0), Day 21, Day 42 and Month 6 which were below, within and above the normal ranges or unknown

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 0, Day 21, Day 42 and Month 6 (M6)

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group	Flu BS2_3-5 Years Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	31	31	60	26 <sup>[31]</sup>
Units: Subjects				
ALAT, Day 0 Unknown	1	1	1	0
ALAT, Day 0 Below	0	0	0	0
ALAT, Day 0 Within	29	30	58	0
ALAT, Day 0 Above	0	0	1	0
ALAT, Day 21 Unknown	1	0	1	0
ALAT, Day 21 Below	0	0	0	0
ALAT, Day 21 Within	30	30	58	0
ALAT, Day 21 Above	0	0	0	0
ALAT, Day 42 Unknown	0	0	2	0
ALAT, Day 42 Below	0	0	0	0
ALAT, Day 42 Within	31	30	55	26
ALAT, Day 42 Above	0	0	1	0
ALAT, M6 Unknown	0	0	1	0
ALAT, M6 Below	0	0	0	0
ALAT, M6 Within	30	29	56	24
ALAT, M6 Above	0	0	1	0
ASAT, Day 0 Unknown	1	1	1	0

ASAT, Day 0 Below	0	0	0	0
ASAT, Day 0 Within	26	29	58	0
ASAT, Day 0 Above	3	1	1	0
ASAT, Day 21 Unknown	1	0	1	0
ASAT, Day 21 Below	0	0	0	0
ASAT, Day 21 Within	30	29	58	0
ASAT, Day 21 Above	0	1	0	0
ASAT, Day 42 Unknown	0	1	2	0
ASAT, Day 42 Below	0	0	0	0
ASAT, Day 42 Within	31	29	55	25
ASAT, Day 42 Above	0	0	1	1
ASAT, M6 Unknown	0	0	1	0
ASAT, M6 Below	0	0	0	0
ASAT, M6 Within	30	28	57	24
ASAT, M6 Above	0	1	0	0
Total Bilirubin, Day 0 Unknown	1	1	1	0
Total Bilirubin, Day 0 Below	0	0	0	0
Total Bilirubin, Day 0 Within	29	28	57	0
Total Bilirubin, Day 0 Above	0	2	2	0
Total Bilirubin, Day 21 Unknown	1	0	1	0
Total Bilirubin, Day 21 Below	0	0	0	0
Total Bilirubin, Day 21 Within	30	28	55	0
Total Bilirubin, Day 21 Above	0	2	3	0
Total Bilirubin, Day 42 Unknown	0	0	2	0
Total Bilirubin, Day 42 Below	0	0	0	0
Total Bilirubin, Day 42 Within	31	30	55	26
Total Bilirubin, Day 42 Above	0	0	1	0
Total Bilirubin, M6 Unknown	0	0	1	0
Total Bilirubin, M6 Below	0	0	0	0
Total Bilirubin, M6 Within	30	28	55	24
Total Bilirubin, M6 Above	0	1	2	0
Bilirubin Conjugated / Direct, Day 0 Unknown	1	1	1	0
Bilirubin Conjugated / Direct, Day 0 Below	0	0	0	0
Bilirubin Conjugated / Direct, Day 0 Within	29	30	58	0
Bilirubin Conjugated / Direct, Day 0 Above	0	0	1	0
Bilirubin Conjugated / Direct, Day 21 Unknown	1	0	1	0
Bilirubin Conjugated / Direct, Day 21 Below	0	0	0	0
Bilirubin Conjugated / Direct, Day 21 Within	30	30	58	0
Bilirubin Conjugated / Direct, Day 21 Above	0	0	0	0
Bilirubin Conjugated / Direct, Day 42 Unknown	0	0	2	0
Bilirubin Conjugated / Direct, Day 42 Below	0	0	0	0
Bilirubin Conjugated / Direct, Day 42 Within	31	30	56	26
Bilirubin Conjugated / Direct, Day 42 Above	0	0	0	0

Bilirubin Conjugated / Direct, M6 Unknown	0	0	1	0
Bilirubin Conjugated / Direct, M6 Below	0	0	0	0
Bilirubin Conjugated / Direct, M6 Within	30	29	57	24
Bilirubin Conjugated / Direct, M6 Above	0	0	0	0
Creatine, Day 0 Unknown	1	1	1	0
Creatine, Day 0 Below	2	0	1	0
Creatine, Day 0 Within	27	29	52	0
Creatine, Day 0 Above	0	1	6	0
Creatine, Day 21 Unknown	1	0	1	0
Creatine, Day 21 Below	3	0	4	0
Creatine, Day 21 Within	27	28	48	0
Creatine, Day 21 Above	0	2	6	0
Creatine, Day 42 Unknown	0	0	2	0
Creatine, Day 42 Below	2	1	3	0
Creatine, Day 42 Within	28	29	52	24
Creatine, Day 42 Above	1	0	1	2
Creatine, M6 Unknown	0	0	1	0
Creatine, M6 Below	1	1	2	1
Creatine, M6 Within	28	28	55	22
Creatine, M6 Above	1	0	0	1
BUN, Day 0 Unknown	1	1	1	0
BUN, Day 0 Below	0	0	2	0
BUN, Day 0 Within	28	30	57	0
BUN, Day 0 Above	1	0	0	0
BUN, Day 21 Unknown	1	0	1	0
BUN, Day 21 Below	1	2	3	0
BUN, Day 21 Within	29	27	55	0
BUN, Day 21 Above	0	1	0	0
BUN, Day 42 Unknown	0	0	2	0
BUN, Day 42 Below	1	2	1	1
BUN, Day 42 Within	29	28	55	23
BUN, Day 42 Above	1	0	0	2
BUN, M6 Unknown	1	0	1	0
BUN, M6 Below	1	0	2	0
BUN, M6 Within	27	28	54	24
BUN, M6 Above	1	1	1	0

Notes:

[31] - The outcome measure for the Flu BS2\_3-5 Group was assessed at Day 42 and Month 6 only.

<b>End point values</b>	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	33 <sup>[32]</sup>	58 <sup>[33]</sup>		
Units: Subjects				
ALAT, Day 0 Unknown	0	0		
ALAT, Day 0 Below	0	0		
ALAT, Day 0 Within	0	0		
ALAT, Day 0 Above	0	0		
ALAT, Day 21 Unknown	0	0		
ALAT, Day 21 Below	0	0		
ALAT, Day 21 Within	0	0		

ALAT, Day 21 Above	0	0		
ALAT, Day 42 Unknown	0	0		
ALAT, Day 42 Below	0	0		
ALAT, Day 42 Within	32	56		
ALAT, Day 42 Above	1	1		
ALAT, M6 Unknown	0	0		
ALAT, M6 Below	0	0		
ALAT, M6 Within	29	52		
ALAT, M6 Above	0	1		
ASAT, Day 0 Unknown	0	0		
ASAT, Day 0 Below	0	0		
ASAT, Day 0 Within	0	0		
ASAT, Day 0 Above	0	0		
ASAT, Day 21 Unknown	0	0		
ASAT, Day 21 Below	0	0		
ASAT, Day 21 Within	0	0		
ASAT, Day 21 Above	0	0		
ASAT, Day 42 Unknown	0	0		
ASAT, Day 42 Below	0	0		
ASAT, Day 42 Within	31	55		
ASAT, Day 42 Above	2	2		
ASAT, M6 Unknown	0	0		
ASAT, M6 Below	0	0		
ASAT, M6 Within	29	50		
ASAT, M6 Above	0	3		
Total Bilirubin, Day 0 Unknown	0	0		
Total Bilirubin, Day 0 Below	0	0		
Total Bilirubin, Day 0 Within	0	0		
Total Bilirubin, Day 0 Above	0	0		
Total Bilirubin, Day 21 Unknown	0	0		
Total Bilirubin, Day 21 Below	0	0		
Total Bilirubin, Day 21 Within	0	0		
Total Bilirubin, Day 21 Above	0	0		
Total Bilirubin, Day 42 Unknown	0	0		
Total Bilirubin, Day 42 Below	0	0		
Total Bilirubin, Day 42 Within	33	55		
Total Bilirubin, Day 42 Above	0	2		
Total Bilirubin, M6 Unknown	0	0		
Total Bilirubin, M6 Below	0	0		
Total Bilirubin, M6 Within	29	51		
Total Bilirubin, M6 Above	0	2		
Bilirubin Conjugated / Direct, Day 0 Unknown	0	0		
Bilirubin Conjugated / Direct, Day 0 Below	0	0		
Bilirubin Conjugated / Direct, Day 0 Within	0	0		
Bilirubin Conjugated / Direct, Day 0 Above	0	0		
Bilirubin Conjugated / Direct, Day 21 Unknown	0	0		
Bilirubin Conjugated / Direct, Day 21 Below	0	0		

Bilirubin Conjugated / Direct, Day 21 Within	0	0		
Bilirubin Conjugated / Direct, Day 21 Above	0	0		
Bilirubin Conjugated / Direct, Day 42 Unknown	0	0		
Bilirubin Conjugated / Direct, Day 42 Below	0	0		
Bilirubin Conjugated / Direct, Day 42 Within	33	57		
Bilirubin Conjugated / Direct, Day 42 Above	0	0		
Bilirubin Conjugated / Direct, M6 Unknown	0	0		
Bilirubin Conjugated / Direct, M6 Below	0	0		
Bilirubin Conjugated / Direct, M6 Within	29	53		
Bilirubin Conjugated / Direct, M6 Above	0	0		
Creatine, Day 0 Unknown	0	0		
Creatine, Day 0 Below	0	0		
Creatine, Day 0 Within	0	0		
Creatine, Day 0 Above	0	0		
Creatine, Day 21 Unknown	0	0		
Creatine, Day 21 Below	0	0		
Creatine, Day 21 Within	0	0		
Creatine, Day 21 Above	0	0		
Creatine, Day 42 Unknown	0	0		
Creatine, Day 42 Below	1	2		
Creatine, Day 42 Within	31	51		
Creatine, Day 42 Above	1	4		
Creatine, M6 Unknown	0	0		
Creatine, M6 Below	0	5		
Creatine, M6 Within	29	47		
Creatine, M6 Above	0	1		
BUN, Day 0 Unknown	0	0		
BUN, Day 0 Below	0	0		
BUN, Day 0 Within	0	0		
BUN, Day 0 Above	0	0		
BUN, Day 21 Unknown	0	0		
BUN, Day 21 Below	0	0		
BUN, Day 21 Within	0	0		
BUN, Day 21 Above	0	0		
BUN, Day 42 Unknown	0	0		
BUN, Day 42 Below	0	0		
BUN, Day 42 Within	32	56		
BUN, Day 42 Above	1	1		
BUN, M6 Unknown	0	0		
BUN, M6 Below	0	0		
BUN, M6 Within	27	53		
BUN, M6 Above	2	0		

Notes:

[32] - The outcome measure for the Flu BS2\_6-9 Group was assessed at Day 42 and Month 6 only.

[33] - The outcome measure for the Flu BS2\_10-17 Group was assessed at Day 42 and Month 6 only.

## Statistical analyses

---

No statistical analyses for this end point

## Adverse events

---

### Adverse events information

---

Timeframe for reporting adverse events:

SAEs: During the entire study period (Day 0 to Month 6), Solicited local and general symptoms: During the 7-day (Days 0-6) post-vaccination period; Unsolicited symptoms: Within the 84-day or from 63-day follow-up period after the 1st and 2nd dose, respectively

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	13.1
--------------------	------

### Reporting groups

Reporting group title	Flu BS1_3-5 Years Group
-----------------------	-------------------------

Reporting group description:

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

On Day 0 (before the first vaccination);  
On Day 21 (before the second vaccination);  
On Day 42 (21 days after the second vaccination);  
At Month 6 (6 months after the first vaccination);

Reporting group title	Flu BS1_6-9 Years Group
-----------------------	-------------------------

Reporting group description:

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

On Day 0 (before the first vaccination);  
On Day 21 (before the second vaccination);  
On Day 42 (21 days after the second vaccination);  
At Month 6 (6 months after the first vaccination);

Reporting group title	Flu BS1_10-17 Years Group
-----------------------	---------------------------

Reporting group description:

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

On Day 0 (before the first vaccination);  
On Day 21 (before the second vaccination);  
On Day 42 (21 days after the second vaccination);  
At Month 6 (6 months after the first vaccination);

Reporting group title	Flu BS2_3-5 Years Group
-----------------------	-------------------------

Reporting group description:

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

On Day 42 (21 days after the second vaccination);  
At Month 6 (6 months after the first vaccination);  
At Month 12 (one year after the first vaccination).

Reporting group title	Flu BS2_6-9 Years Group
-----------------------	-------------------------

Reporting group description:

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

On Day 42 (21 days after the second vaccination);  
At Month 6 (6 months after the first vaccination);  
At Month 12 (one year after the first vaccination).

Reporting group title	Flu BS2_10-17 Years Group
-----------------------	---------------------------

Reporting group description:

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:

On Day 42 (21 days after the second vaccination);  
At Month 6 (6 months after the first vaccination);  
At Month 12 (one year after the first vaccination).

<b>Serious adverse events</b>	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 31 (3.23%)	1 / 31 (3.23%)	1 / 60 (1.67%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Facial bones fracture			
subjects affected / exposed	0 / 31 (0.00%)	0 / 31 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Forearm fracture			
subjects affected / exposed	0 / 31 (0.00%)	1 / 31 (3.23%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 31 (0.00%)	0 / 31 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Ectopic pregnancy			
subjects affected / exposed	0 / 31 (0.00%)	0 / 31 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Ranula			
subjects affected / exposed	0 / 31 (0.00%)	0 / 31 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
alternative assessment type: Non-systematic			

subjects affected / exposed	0 / 31 (0.00%)	0 / 31 (0.00%)	1 / 60 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Febrile infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 31 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 31 (3.23%)	0 / 31 (0.00%)	0 / 60 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Flu BS2_3-5 Years Group	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	1 / 30 (3.33%)	0 / 34 (0.00%)	3 / 58 (5.17%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
<b>Injury, poisoning and procedural complications</b>			
Facial bones fracture			
subjects affected / exposed	0 / 30 (0.00%)	0 / 34 (0.00%)	1 / 58 (1.72%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Forearm fracture			
subjects affected / exposed	0 / 30 (0.00%)	0 / 34 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vascular disorders</b>			
Haematoma			
subjects affected / exposed	1 / 30 (3.33%)	0 / 34 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pregnancy, puerperium and perinatal conditions</b>			
Ectopic pregnancy			

subjects affected / exposed	0 / 30 (0.00%)	0 / 34 (0.00%)	1 / 58 (1.72%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
Ranula			
subjects affected / exposed	0 / 30 (0.00%)	0 / 34 (0.00%)	1 / 58 (1.72%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
Asthma			
alternative assessment type: Non-systematic			
subjects affected / exposed	0 / 30 (0.00%)	0 / 34 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Febrile infection			
subjects affected / exposed	1 / 30 (3.33%)	0 / 34 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 30 (0.00%)	0 / 34 (0.00%)	0 / 58 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Flu BS1_3-5 Years Group	Flu BS1_6-9 Years Group	Flu BS1_10-17 Years Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 31 (96.77%)	25 / 31 (80.65%)	56 / 60 (93.33%)
<b>Nervous system disorders</b>			
Headache (Non-systematic)			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 31 (3.23%)	9 / 31 (29.03%)	30 / 60 (50.00%)
occurrences (all)	1	14	47

Somnolence			
subjects affected / exposed	11 / 31 (35.48%)	0 / 31 (0.00%)	0 / 60 (0.00%)
occurrences (all)	16	0	0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	15 / 31 (48.39%)	7 / 31 (22.58%)	19 / 60 (31.67%)
occurrences (all)	22	10	22
Influenza like illness			
subjects affected / exposed	1 / 31 (3.23%)	1 / 31 (3.23%)	2 / 60 (3.33%)
occurrences (all)	1	1	2
Pain			
subjects affected / exposed	19 / 31 (61.29%)	24 / 31 (77.42%)	51 / 60 (85.00%)
occurrences (all)	29	40	92
Swelling			
subjects affected / exposed	13 / 31 (41.94%)	13 / 31 (41.94%)	21 / 60 (35.00%)
occurrences (all)	16	18	28
Arthralgia			
subjects affected / exposed	0 / 31 (0.00%)	7 / 31 (22.58%)	11 / 60 (18.33%)
occurrences (all)	0	10	14
Diarrhoea			
subjects affected / exposed	6 / 31 (19.35%)	0 / 31 (0.00%)	0 / 60 (0.00%)
occurrences (all)	7	0	0
Fatigue			
subjects affected / exposed	0 / 31 (0.00%)	13 / 31 (41.94%)	29 / 60 (48.33%)
occurrences (all)	0	18	37
Gastro-intestinal symptoms			
subjects affected / exposed	0 / 31 (0.00%)	7 / 31 (22.58%)	18 / 60 (30.00%)
occurrences (all)	0	11	21
Headache (Systematic)			
subjects affected / exposed	1 / 31 (3.23%)	9 / 31 (29.03%)	30 / 60 (50.00%)
occurrences (all)	1	14	47
Irritability			
subjects affected / exposed	9 / 31 (29.03%)	0 / 31 (0.00%)	0 / 60 (0.00%)
occurrences (all)	13	0	0
Myalgia			

subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	6 / 31 (19.35%) 10	21 / 60 (35.00%) 26
Chills subjects affected / exposed occurrences (all)	7 / 31 (22.58%) 11	7 / 31 (22.58%) 8	18 / 60 (30.00%) 24
Eye disorders Conjunctivitis subjects affected / exposed occurrences (all)	3 / 31 (9.68%) 3	1 / 31 (3.23%) 1	0 / 60 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	5 / 31 (16.13%) 7	1 / 31 (3.23%) 1	0 / 60 (0.00%) 0
Skin and subcutaneous tissue disorders Eczema subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	0 / 31 (0.00%) 0	0 / 60 (0.00%) 0
Erythema subjects affected / exposed occurrences (all)	14 / 31 (45.16%) 18	16 / 31 (51.61%) 20	23 / 60 (38.33%) 34
Hyperhidrosis subjects affected / exposed occurrences (all)	4 / 31 (12.90%) 4	4 / 31 (12.90%) 4	9 / 60 (15.00%) 10
Musculoskeletal and connective tissue disorders Pain in extremity subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	2 / 31 (6.45%) 2	0 / 60 (0.00%) 0
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	4 / 31 (12.90%) 4	1 / 31 (3.23%) 2	5 / 60 (8.33%) 5
Nasopharyngitis subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 3	0 / 31 (0.00%) 0	3 / 60 (5.00%) 4
Rhinitis			

subjects affected / exposed occurrences (all)	3 / 31 (9.68%) 3	1 / 31 (3.23%) 1	2 / 60 (3.33%) 2
Bronchitis subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	0 / 31 (0.00%) 0	2 / 60 (3.33%) 2
Gastroenteritis subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	0 / 31 (0.00%) 0	0 / 60 (0.00%) 0
Lice infestation subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	1 / 31 (3.23%) 1	0 / 60 (0.00%) 0
Otitis externa subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	0 / 31 (0.00%) 0	1 / 60 (1.67%) 1
Otitis media subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 31 (0.00%) 0	1 / 60 (1.67%) 1
Viral infection subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	2 / 31 (6.45%) 2	1 / 60 (1.67%) 1

<b>Non-serious adverse events</b>	Flu BS2_3-5 Years Group	Flu BS2_6-9 Years Group	Flu BS2_10-17 Years Group
Total subjects affected by non-serious adverse events subjects affected / exposed	26 / 30 (86.67%)	26 / 34 (76.47%)	50 / 58 (86.21%)
Nervous system disorders Headache (Non-systematic) alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 4	10 / 34 (29.41%) 13	31 / 58 (53.45%) 50
Somnolence subjects affected / exposed occurrences (all)	9 / 30 (30.00%) 11	0 / 34 (0.00%) 0	0 / 58 (0.00%) 0
General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all)	15 / 30 (50.00%) 22	9 / 34 (26.47%) 11	12 / 58 (20.69%) 14

Influenza like illness			
subjects affected / exposed	1 / 30 (3.33%)	0 / 34 (0.00%)	4 / 58 (6.90%)
occurrences (all)	1	0	4
Pain			
subjects affected / exposed	21 / 30 (70.00%)	25 / 34 (73.53%)	45 / 58 (77.59%)
occurrences (all)	38	42	75
Swelling			
subjects affected / exposed	9 / 30 (30.00%)	9 / 34 (26.47%)	25 / 58 (43.10%)
occurrences (all)	13	13	38
Arthralgia			
subjects affected / exposed	2 / 30 (6.67%)	7 / 34 (20.59%)	14 / 58 (24.14%)
occurrences (all)	2	9	17
Diarrhoea			
subjects affected / exposed	4 / 30 (13.33%)	0 / 34 (0.00%)	0 / 58 (0.00%)
occurrences (all)	5	0	0
Fatigue			
subjects affected / exposed	0 / 30 (0.00%)	11 / 34 (32.35%)	24 / 58 (41.38%)
occurrences (all)	0	15	36
Gastro-intestinal symptoms			
subjects affected / exposed	0 / 30 (0.00%)	6 / 34 (17.65%)	12 / 58 (20.69%)
occurrences (all)	0	7	13
Headache (Systematic)			
subjects affected / exposed	4 / 30 (13.33%)	10 / 34 (29.41%)	31 / 58 (53.45%)
occurrences (all)	4	13	50
Irritability			
subjects affected / exposed	9 / 30 (30.00%)	0 / 34 (0.00%)	0 / 58 (0.00%)
occurrences (all)	14	0	0
Myalgia			
subjects affected / exposed	1 / 30 (3.33%)	7 / 34 (20.59%)	24 / 58 (41.38%)
occurrences (all)	1	12	29
Chills			
subjects affected / exposed	3 / 30 (10.00%)	3 / 34 (8.82%)	17 / 58 (29.31%)
occurrences (all)	4	4	22
Eye disorders			
Conjunctivitis			

subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 34 (0.00%) 0	1 / 58 (1.72%) 1
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	5 / 30 (16.67%) 10	2 / 34 (5.88%) 3	2 / 58 (3.45%) 3
Skin and subcutaneous tissue disorders Eczema subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 34 (0.00%) 0	0 / 58 (0.00%) 0
Erythema subjects affected / exposed occurrences (all)	14 / 30 (46.67%) 21	12 / 34 (35.29%) 16	23 / 58 (39.66%) 30
Hyperhidrosis subjects affected / exposed occurrences (all)	5 / 30 (16.67%) 6	6 / 34 (17.65%) 6	9 / 58 (15.52%) 10
Musculoskeletal and connective tissue disorders Pain in extremity subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 34 (0.00%) 0	0 / 58 (0.00%) 0
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 5	0 / 34 (0.00%) 0	2 / 58 (3.45%) 3
Nasopharyngitis subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 6	2 / 34 (5.88%) 2	4 / 58 (6.90%) 5
Rhinitis subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	1 / 34 (2.94%) 1	1 / 58 (1.72%) 1
Bronchitis subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 5	0 / 34 (0.00%) 0	1 / 58 (1.72%) 1
Gastroenteritis subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	0 / 34 (0.00%) 0	1 / 58 (1.72%) 1

Lice infestation			
subjects affected / exposed	2 / 30 (6.67%)	1 / 34 (2.94%)	1 / 58 (1.72%)
occurrences (all)	2	1	1
Otitis externa			
subjects affected / exposed	0 / 30 (0.00%)	0 / 34 (0.00%)	1 / 58 (1.72%)
occurrences (all)	0	0	1
Otitis media			
subjects affected / exposed	2 / 30 (6.67%)	0 / 34 (0.00%)	0 / 58 (0.00%)
occurrences (all)	2	0	0
Viral infection			
subjects affected / exposed	1 / 30 (3.33%)	0 / 34 (0.00%)	3 / 58 (5.17%)
occurrences (all)	1	0	3

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 August 2010	Following the very high immune response after the first two doses of vaccine, in addition to the decreased perception of the pandemic threat by the public and in the light of a potential increase of overall reactogenicity, the added value of the booster dose was considered limited by the investigators. Thus no subject enrolled in Flu D-Pan H1N1-023 study were vaccinated with the booster dose. The safety follow-up was thus reduced to Month 12, i.e. 12 months after the first vaccination, instead of 12 months after the booster dose.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported